Back to Agenda
Session 8: Patient Access
Session Chair(s)
Michael Muenzberg
Vice President, Director Medical Affairs Biosimilars, Ares Trading S.A, Switzerland
Biologic medicines play an increasing role in the patient care across a growing number of disease areas. Access to these modern therapies remains restricted due to the high cost of these medicines. This session will look at the current barriers to accessing existing biologic therapies and how the emergence of biosimilar medicines across Europe and in the US brings the promise to overcome those, offering opportunities for health systems to expand access for more patients, but also foster investment in new areas of care while providing relief on health care budgets.
Speaker(s)
Paulo Moreira
Global Head of Clinical Operations, Agenus, United States
Increasing Information for Patients About Accessing Treatments Biosimilars and Clinical Trials
John Carlsen, MHA
Vice President, Covance Market Access Services Inc., United States
An Overview of Current Biosimilars Reimbursement Practive and Medicare
Leigh Purvis, MPA
Director, Health Services Research, American Association of Retired Persons (AARP), United States
AARP’s Perspective on Access to Biologic Medicines
Panel Discussion
, All Session Speakers, United States
Have an account?